Hutchmed (China) (HCM) said late Monday it completed enrollment in the registration phase of a phase II trial to assess the efficacy, safety and tolerability of savolitinib in gastric cancer patients with MET amplification.
A total of 64 patients have been enrolled in the trial.
If positive, the company may begin plans to apply for marketing authorization of savolitinib for gastric cancer in China later this year, it said.
Savolitinib is being jointly developed by AstraZeneca (AZN) and Hutchmed, and commercialized by AstraZeneca.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。